RDNT
Get informed when a big investor buys or sells
+ FollowOvervalued by 134% based on the discounted cash flow analysis.
| Market cap | $5.16 Billion |
|---|---|
| Enterprise Value | $6.65 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.25 |
| Beta | 1.36 |
| Outstanding Shares | 77,057,835 |
| P/E Ratio | -371.67 |
|---|---|
| PEG | - |
| Price to Sales | 2.27 |
| Price to Book Ratio | 3.61 |
| Enterprise Value to Revenue | 3.1 |
| Enterprise Value to EBIT | 65.63 |
| Enterprise Value to Net Income | -469 |
| Total Debt to Enterprise | 0.29 |
| Debt to Equity | 1.8 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 24.44% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Holdings and activity of institutional investors.
| Ownership % | 0.70%▼ 101.82% |
|---|---|
| Total Invested | $33.44M▼ 99.22% |
| Investors Holding | 14▼ 334.00% |
No data
Controls Medicare and Medicaid policy; legislative movements to expand Medicare to include dental benefits would represent a massive revenue catalyst for the lab industry.
Directly oversees the FDA, which regulates dental materials and the 3D printing technologies increasingly used in dental labs.